Diligence memo · auto-generated · as of July 2, 2026

Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Advanced Cell Technology, Inc. operates in Biotechnology, based in WORCESTER.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Advanced Cell Technology, Inc. has raised $2.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.8M on 2009-11-12.

Most recent recorded round closed around 2009-11-12.

Valuation (modeled)modeled

Provath models Advanced Cell Technology, Inc. at approximately $123M (range $2.0M–$967M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.19× the median modeled value of Seed Biotechnology companies in 2007–2009 (47 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 16.6 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 33% of Biotechnology peers (4293 compared).

Modeled value ranks above 63% of those peers.

Closest niche peers: Bioassets Development Corp, Aubrey Inc, EndoMetabolic Solutions, Inc., Targegen Inc, Promethean Surgical Devices, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.